Merck Manual

Please confirm that you are a health care professional

honeypot link

Metachromatic Leukodystrophy

(Sulfatide Lipidosis)


Matt Demczko

, MD, Mitochondrial Medicine, Children's Hospital of Philadelphia

Reviewed/Revised Oct 2021 | Modified Nov 2021

Metachromatic leukodystrophy is a sphingolipidosis Sphingolipidoses Lysosomal enzymes break down macromolecules, either those from the cell itself (eg, when cellular structural components are being recycled) or those acquired outside the cell. Inherited defects... read more , an inherited disorder of metabolism, caused by arylsulfatase A deficiency. There are several forms, the most severe of which causes progressive paralysis and dementia resulting in death by age 10 years.

For more information, see table Some Sphingolipidoses Some Sphingolipidoses Some Sphingolipidoses .

In metachromatic leukodystrophy, arylsulfatase A deficiency causes metachromatic lipids to accumulate in the white matter of the central nervous system, peripheral nerves, kidney, spleen, and other visceral organs; accumulation in the nervous system causes central and peripheral demyelination. Numerous mutations exist; patients vary in age at onset and speed of progression.

The infantile form is characterized by progressive paralysis and dementia usually beginning before age 4 years and resulting in death about 5 years after onset of symptoms.

The juvenile form manifests between 4 years and 16 years of age with gait disturbance, intellectual impairment, and findings of peripheral neuropathy. Contrary to the infantile form, deep tendon reflexes are usually brisk.

There is also a milder adult form.

Diagnosis of metachromatic leukodystrophy is suggested clinically and by findings of decreased nerve conduction velocity; it is confirmed by DNA analysis and/or detecting enzyme deficiency in white blood cells or cultured skin fibroblasts. (Also see testing for suspected inherited disorders of metabolism Initial testing Most inherited disorders of metabolism (inborn errors of metabolism) are rare, and therefore their diagnosis requires a high index of suspicion. Timely diagnosis leads to early treatment and... read more .)

There is currently no effective treatment for metachromatic leukodystrophy in patients with advanced symptoms. Bone marrow or stem cell transplantation may stabilize neurocognitive function in mildly symptomatic forms of the disease. Several other therapeutic options are currently being investigated, primarily in late infantile forms of the disease, including gene therapy, enzyme replacement therapy, substrate reduction therapy, and, potentially, enzyme enhancement therapy.

More Information

The following is an English-language resource that may be useful. Please note that THE MANUAL is not responsible for the content of this resource.

NOTE: This is the Professional Version. CONSUMERS: View Consumer Version
quiz link

Test your knowledge

Take a Quiz!